The short version of GHRH receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-13 and is reviewed periodically as new material appears.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
38 Mod 3): Nimitz-class aircraft carrier, Arleigh Burke-class destroyer, Ticonderoga-class cruiser, Oliver Hazard Perry-class frigate, Wasp-class amphibious assault ship, Tarawa-class amphibious assault ship, Whidbey Island-class dock landing ship, Harpers Ferry-class dock landing ship, Austin-class amphibious transport dock, Blue Ridge-class command ship, Cyclone-class patrol ship, Mark VI patrol boat Marine Corps: LAV-25 Coast Guard (Mk. 38 Mod 0, Mk. 38 Mod 2 and Mk. 38 Mod 3): Reliance-class cutter, Hamilton-class cutter, Sentinel-class cutter, Island-class cutter, USCGC Alex Haley, future Heritage-class cutter
== Structure == There are three types of muscle tissue in vertebrates: skeletal, cardiac, and smooth. Skeletal and cardiac muscle are types of striated muscle tissue. Smooth muscle is non-striated. There are three types of muscle tissue in invertebrates that are based on their pattern of striation: transversely striated, obliquely striated, and smooth muscle. In arthropods there is no smooth muscle. The transversely striated type is the most similar to the skeletal muscle in vertebrates. Vertebrate skeletal muscle tissue is an elongated, striated muscle tissue, with the fibres ranging from a few millimeters to several inches in length and from 10 to 100 micrometers in width. Skeletal striated muscle tissue is arranged in regular, parallel bundles of myofibrils, which contain many contractile units known as sarcomeres, which give the tissue its striated (striped) appearance. Skeletal muscle is voluntary muscle, anchored by tendons or sometimes by aponeuroses to bones, and is used to affect skeletal movement such as locomotion and to maintain posture. Postural control is generally maintained as an unconscious reflex, but the responsible muscles can also react to conscious control. The body mass of an average adult man is made up of 42% of skeletal muscle, and an average adult woman is made up of 36%. Cardiac muscle tissue is found only in the walls of the heart as myocardium, and it is an involuntary muscle controlled by the autonomic nervous system. Cardiac muscle tissue is striated like skeletal muscle, containing sarcomeres in highly regular arrangements of bundles.
Tramadol can have pharmacodynamic, pharmacokinetic, and pharmacogenetic interactions. Tramadol is metabolized by CYP2D6 enzymes which contributes to the metabolism of approximately 25% of all medications. Any medications with the ability to inhibit or induce these enzymes may interact with tramadol. These include common antiarrhythmics, antiemetics, antidepressants (sertraline, paroxetine, and fluoxetine in particular), antipsychotics, analgesics, and tamoxifen.- Due to tramadol's serotonergic effects, tramadol has the potential to contribute to the development of an acute or chronic hyper-serotonin state called serotonin syndrome when used concurrently with other pro-serotonergic medications such as antidepressants (SSRIs, SNRIs, tricyclics, MAOIs), antipsychotics, triptans, cold medications containing dextromethorphan, and some herbal products such as St. John's wort. Concurrent use of 5-HT3 antagonists such as ondansetron, dolasetron, and palonosetron may reduce the effectiveness of both drugs. Tramadol also acts as an opioid agonist and thus can increase the risk for side effects when used with other opioid and opioid-containing analgesics (such as morphine, pethidine, tapentadol, oxycodone, fentanyl, and Tylenol 3). Tramadol increases the risk for seizures by lowering the seizure threshold. Using other medications that lower seizure threshold – such as antipsychotic medications, bupropion (an anti-depressant and smoking cessation drug), and amphetamines – can further increase this risk.
Recent size estimates in 2023 have this sauropod reaching lengths of up to 44 m (144 ft) long and placed in a colossal weight range of around 110000–170000 kg (240000–370000 lb). If these upper estimates are true, Bruhathkayosaurus would have rivaled the blue whale and Perucetus colossus as one of the largest animals to have ever existed. The largest carnivorous dinosaur was Spinosaurus, reaching a length of 12.6 to 18 meters (41 to 59 ft) and weighing 7 to 20.9 metric tons (7.7 to 23.0 short tons). Other large carnivorous theropods included Giganotosaurus, Carcharodontosaurus, and Tyrannosaurus. Therizinosaurus and Deinocheirus were among the tallest of the theropods. The largest ornithischian dinosaur was probably the hadrosaurid Shantungosaurus giganteus, which measured 16.6 meters (54 ft). The largest individuals may have weighed as much as 16 metric tons (18 short tons).
The Mini DisplayPort connector was developed by Apple for use in their computer products. It was first announced in October 2008 for use in the new MacBooks and Cinema Display. In 2009, VESA adopted it as an official standard, and in 2010 the specification was merged into the main DisplayPort standard with the release of DisplayPort 1.2. Apple freely licenses the specification to VESA. The Mini DisplayPort (mDP) connector is a 20-pin single-orientation connector with a friction lock. Unlike the full-size connector, it does not have an option for a mechanical latch. The mDP receptacle has dimensions of 7.50 mm (width) × 4.60 mm (height) × 4.99 mm (depth). The mDP pin assignments are the same as the full-size DisplayPort connector.
Sources: en.wikipedia.org
== Nearby points of interest == Gypsy Cove, known for its Magellanic penguins, and Cape Pembroke, the easternmost point of the Falklands, lie nearby. Gypsy Cove is four miles (6 km) from Stanley and can be reached by taxi or on foot.
=== As biochemical reactors === Synthetic condensates offer a way to probe cellular function and organization with high spatial and temporal control, but can also be used to modify or add functionality to the cell. One way this is accomplished is by modifying the condensate networks to include binding sites for other proteins of interest, thus allowing the condensate to serve as a scaffold for protein release or recruitment. These binding sites can be modified to be sensitive to light activation or small molecule addition, thus giving temporal control over the recruitment of a specific protein of interest. By recruiting specific proteins to condensates, reactants can be concentrated to increase reaction rates or sequestered to inhibit reactivity. More importantly, by spatially organizing the proximity of enzymes in a complex pathway, synthetic condensates can be used to direct the metabolic flux of branched reactions. In an extreme example of using RNA-based synthetic organelle TEARS to organize violacine biosynthesis pathway in E. coli, the side reaction that produces deoxychromoviridans over the desired product deoxyviolacine can be abolished completely by TEARs. In addition to protein recruitment, condensates can also be designed which release proteins in response to certain stimuli. In this case, a protein of interest can be fused to a scaffold protein via a photocleavable linker. Upon irradiation, the linker is broken, and the protein is released from the condensate.
=== Simulated chemical pathways === In 2020, chemists described possible chemical pathways from nonliving prebiotic chemicals to complex biochemicals that could give rise to living organisms, based on a new computer program named AllChemy.
Higher pressure than CCC (typical operation pressures of 40–160 bar vs 5–25 bar) As the pressure drops on the LiLiChro's rotor with the new cells is less than 10bar, this disadvantage has been overcome by the technology and the all-new rotary union seals will last for years of continuous use. Rotary seal wear over time
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.